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Abstract
Background: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor
monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to
a higher rate of neurocognitive impairment.
Methods: In this observational, cross-sectional study we included patients with plasma virological suppression ($1 year)
without concomitant major neurocognitive confounders, currently receiving for $1 year boosted lopinavir or darunavir as
monotherapy or as triple ART. Neurocognitive impairment was defined as per the 2007 consensus of the American
Association of Neurology. The association between neurocognitive impairment and protease inhibitor monotherapy,
adjusted by significant confounders, was analysed.
Results: Of the 191 included patients - triple therapy: 96, 1–2 years of monotherapy: 40 and .2 years of monotherapy: 55 -
proportions (95% CI) with neurocognitive impairment were: overall, 27.2% (20.9–33.6); triple therapy, 31.6% (22.1–41.0);
short-term monotherapy, 25.0% (11.3–38.7); long-term monotherapy: 21.4% (10.5–32.3); p = 0.38. In all groups,
neurocognitive impairment was mildly symptomatic or asymptomatic by self-report. There were not significant differences
in Global Deficit Score by group. In the regression model confounding variables for neurocognitive impairment were years
on ART, ethnicity, years of education, transmission category and the HOMA index. Adjusted by these variables the Odds
Ratio (95% CI) for neurocognitive impairment of patients receiving short-term monotherapy was 0.85 (0.29–2.50) and for
long-term monotherapy 0.40 (0.14–1.15).
Conclusions: Compared to triple drug antiretroviral therapy, monotherapy with lopinavir/ritonavir or darunavir/ritonavir in
patients with adequate plasma suppression was not associated with a higher rate of asymptomatic neurocognitive
impairment than triple drug ART.
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Introduction
Antiretroviral therapy (ART) prevents severe HIV-associated
neurocognitive disorders (HAND). However milder forms of
HAND are still prevalent despite widespread use of ART [1].
Suboptimal ART penetration into the central nervous system
could theoretically be the cause of the remaining high prevalence
of milder forms of HAND.
In patients with tolerability issues, who remain virologically
suppressed with triple-drug ART for at least six months, a switch
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to protease inhibitor monotherapy with lopinavir or darunavir is
an effective alternative in the majority of patients [2,3,4,5]. Despite
these results, protease inhibitor monotherapy is a controversial
strategy [6] not recommended by all expert guidelines. The 2012
recommendations of the International Antiviral Society–USA
panel mention concern about poor central nervous system
penetration as one of the reasons for not recommending protease
inhibitor monotherapy [7].
Concerns about higher risk of neurocognitive impairment in
patients receiving protease inhibitor monotherapy are based on its
perceived low CNS penetration and effectiveness (CPE) score [8],
not in the results of clinical trials or cohort studies. It should be
noted that the CPE score has not been validated for protease
inhibitor monotherapy. The largest clinical trials of protease
inhibitor monotherapy have not included detailed neurocognitive
testing [9]. Small studies including neurocognitive assessment have
not found and association between protease inhibitor monother-
apy and higher of rates neurocognitive impairment [10,11].
Indirect data of neurological damage such as higher levels of
biomarkers in patients on monotherapy have been reported [12].
There is clearly a need for more empirical data about the risk of
neurocognitive impairment in patients receiving protease inhibitor
monotherapy. To investigate if protease inhibitor monotherapy is
associated with higher rates of neurocognitive impairment we have
evaluated neurocognitive function in 191 virologically suppressed
patients receiving protease inhibitors as monotherapy or as triple-
drug ART.
Patients and Methods
Study design and setting
This cross-sectional study compared the prevalence of neuro-
cognitive impairment in virologically suppressed patients on triple-
drug ART (two nucleoside/nucleotide reverse transcriptase
inhibitor plus a protease inhibitor) versus protease inhibitor
monotherapy. The study was conducted from April 2011 to June
2012 at the HIV Units of La Paz and the Doce de Octubre
Hospitals in Madrid, Spain. All participants completed a
comprehensive neurocognitive test battery, medical assessment
and phlebotomy at the same visit.
Patients
All HIV-1 infected patients aged 18 years or over with at least
one year of virological suppression while receiving lopinavir/
ritonavir or darunavir/ritonavir as monotherapy or with two
nucleoside/nucleotide reverse transcriptase inhibitor (triple ther-
apy) were selected as study candidates. Virologic suppression was
defined as two measurements of plasma HIV-1 RNA below 50
copies/mL separated by at least one year. A single virologic
rebound of 50–500 HIV-RNA copies/ml (single blip) was allowed
in the year prior to the inclusion.
Exclusion criteria were: presence of active central nervous
system opportunistic disease, neuromuscular disease which could
limit the performance of neurocognitive testing, use of psychiatric
medications that may interfere with results of the neurocognitive
evaluation, substance abuse during the previous three months,
alcohol abuse during the six previous months and diagnosis of
psychotic disorders according to the Diagnostic and Statistical
Manual of Mental Health Disorders (DSM-IV-TR).
Patients who were receiving triple therapy at inclusion, but had
previously received protease inhibitor monotherapy for at least one
year were also excluded. Reasons for stopping monotherapy in
these patients are reported in table S1.
The study was systematically offered to all patients who fulfilled
all the inclusion and none of the exclusion criteria. Criteria used
for recruiting were identical for patients receiving monotherapy or
triple therapy. Recruitment flow-chart is reported as figure S1.
Ethics Statement
This study and its procedures were conduced according with the
principles expressed in the Declaration of Helsinki. The local
Ethics Committees for Clinical Research of each participant
hospital - ‘‘Comite Etico de Investigacio´n Clinica del Hospital
Universitario La Paz de Madrid & Comite Etico de Investigacio´n
Clinica del Hospital Universitario Doce de Octubre de Madrid -
and the Institutional review boards of both hospitals - Comision de
Investigacion del Hospital Universitario La Paz de Madrid &
Comision de Investigacion del Hospital Universitario Doce de
Octubre de Madrid - approved the protocol and all the above
procedures. All participants provided written informed consent.
Neurobehavioral and Psychiatric examination
All participants completed the HADS-D (Hospital Anxiety and
Depression Scale) [13] questionnaire during the screening visit.
Patients who scored $8 in the depression subscale (HADS-D)
were interviewed by one psychologist with experience in conduct-
ing structured interviews to generate a DSM-IV-TR diagnosis of
major depression. Subjects with current major depression were
excluded but could be subsequently enrolled if they achieved
clinical remission after six months of antidepressive treatment.
A psychologist blinded to treatment group evaluated all
participants. Following the American Association of Neurology
consensus [14] neurocognitive testing included a battery of 14
tests, covering 7 cognitive domains (Table S2). To estimate the
premorbid neurocognitive performance participants completed
the Wechsler Adult Intelligence Scale (WAIS-III) Vocabulary test.
The best available normative standards for the Spanish population
were used, which correct for effects of age, gender, and education.
Raw tests scores were converted to demographically corrected
standard scores (z scores), by a computerized application. The Z
scores for each of the neurocognitive domains assessed were
calculated as the mean of the two tests used to evaluate each
domain. Neurocognitive impairment was defined as ‘‘acquired
impairment in cognitive functioning, involving at least two ability
domains, documented by performance of at least 1 SD below the
mean for age-education-appropriate norms on standardized
neuropsychological tests’’ [14] Daily functional performance was
assessed by self-report questions related to cognitive abilities and
general functioning. Neurocognitive performance was quantified
using the Global Deficit Score (GDS) [15].
Data collection
Socio-demographical data including educational level and use
of alcohol/illicit drugs, medical history (general and HIV
infection), adherence determined by self-reported missed doses in
the last 30 days, use of ART and other prescribed medications
were obtained by self-report questionnaires and from clinical and
laboratory records.
Fasting blood plasma samples were collected and levels of
glucose, cholesterol (total, low-, and high-density lipoprotein),
triglycerides, and insulin were measured using standard methods
in the sites’ certified clinical laboratories. Insulin resistance was
calculated using the homeostasis model assessment of insulin
resistance (HOMA-IR) forrmula: (insulin in mU/ml x glucose in
mmol/L)/22.5. Current CD4 cell count and HIV-1 viral load
were determined, respectively, using flow citometry and autom-
atized RNA extraction in an AmpliPrep instrument (Roche
PI Monotherapy and Neurocognitive Impairment
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Diagnostics, Mannheim, Germany) followed by quantification
using the COBAS AMPLICOR MONITOR HIV-1 test version
1.5 (Roche Diagnostic Systems, Branchburg, NJ).
Comorbidities previously associated with neurocognitive im-
pairment were classified in three categories: medical comorbidities
(hypertension, dyslipidaemia, diabetes mellitus, ischemic heart
disease, heart failure, chronic renal failure, thyroid disorders and
peripheral arterial disease); neurological comorbidities (history of
central nervous system infection, stroke, cerebral trauma and
epilepsy) and psychiatric comorbidities (history of past mood
disorders and current or past anxiety disorders). We categorized
hepatitis C infection as no infection, past infection (spontaneous
viral clearance or successfully treated) and active infection
(detectable HCV plasma viremia).
We categorized monotherapy as short-term (S-MT) -less than
two years- and long-term (L-MT)-more than two years- and
calculated the CPE for each ART regimens according to the 2010
version [16].
Statistical Methods
Sample characteristics were described using absolute and
relative frequencies for categorical variables and means 6 SD or
median (IQR) for continuous variables. Chi-square test and
Student’s t or the nonparametric Mann-Whitney U-test was used
to compare baseline characteristics. Association between neuro-
cognitive impairment and type of ART (S-MT and L-MT
monotherapy or triple therapy) was analysed. A multivariate
logistic regression with an estimative approach was fitted with
presence versus absence of neurocognitive impairment as the
dependent variable. Reference category for type of ART was triple
therapy and odds ratios (ORs) for presence of neurocognitive
impairment in patients receiving monotherapy were obtained. We
evaluated as potential confounders: age, sex, ethnicity, risk group
for HIV transmission, years on ART, years with suppressed HIV
viremia, prior single blip, CD4 count (current and nadir), years of
education, use of non-prescribed drugs, presence of medical,
neurological or psychiatric comorbidities, co-infection with hep-
atitis C, use of statin, triglycerides, total cholesterol/HDL ratio
and HOMA-IR. Variables producing a change greater than 15%
in the OR of interest were retained in the model. All analyses were
performed using the STATA statistical package (V.11.1, Stata
Corporation, College Station, Texas, USA). All tests were 2-sided,
p values,0.05 were considered significant.
Results
Study Population
We identified 417 potential study candidates (Figure S1). We
finally recruited 196 subjects. Two patients on monotherapy and
three on triple therapy were excluded due to HIV-1 RNA above
50 copies/ml at the initial study visit. Finally we included 191
patients 95 (48%) in the triple therapy group, 40 (20.2%) in the S-
MT group and 56 (28.3%) in the L-MT group (Tables 1 and 2).
Patients in the monotherapy groups were slightly older (p = 0.04
for S-MT and p,0.01 for L-MT) and more frequently Caucasians
(p,0.01 for S-MT). They were infected earlier (p,0.01 for S-
MT), had higher current (p,0.05 for S-TM) and CD4 nadirs
(p,0.05 for S-MT), were suppressed for a longer time (p,0.01 for
L-MT), were less likely to present blips (p,0.01 for S-MT) and
received ART for a longer time (p,0.01 for S-MT and p,0.05 for
L-MT). Patients receiving monotherapy had a worse metabolic
profile: triglycerides (p,0.05 for L-MT), cholesterol/HDL ratio
and the HOMA index (p,0.05 for L-MT) were higher.
We also found the following differences between monotherapy
groups: Patients on the S-MT group had a longer duration of the
HIV infection (p,0.01), were previously treated with triple
therapy longer (p,0.01), were receiving more frequently daruna-
vir/ritonavir (p,0.05) and had higher rates of active HCV
coinfection (p,0.05).
Table 1. Demographics infection risk, education and HIV disease status.
TT N = 95 S-MT (1–2 years) N = 40 L-MT (.2 years) N = 56 p,0.05
Male. N (%) 70 (73.7) 29 (72.5) 41 (73.2)
Age. Median (IQR) 44.7 (40.6–48.4) 47.3 (44.8–49.1) 47.7 (44.9–52.7) S-MT, L-MT vs. TT
Ethnicity. N (%)
Caucasian 79 (83.2) 40 (100.0) 52 (92.9) S-MT vs. TT
Other 16 (16.8) 0 (0.0) 4 (7.1)
Way of transmission. N (%)
Men who have sex with men 29 (30.5) 9 (22.5) 21 (37.5)
Men who have sex with women 30 (31.6) 9 (22.5) 16 (28.6)
Intravenous drug user 30 (31.6) 17 (42.5) 17 (30.4)
Other 6 (6.3) 5 (12.5) 2 (3.6)
Years of education. Mean (SD) 11.3 (4.1) 10.4 (4.4) 10.3 (4.5)
AIDS. N (%) 60 (63.2) 23 (59.0) 36 (64.3)
Years infected with HIV. Median (IQR) 15.1 (7.2–19.9) 20.2 (14.8–23.4) 15.7 (12.0–19.3) S-MT vs. TT, L-MT
CD4 nadir (c/mm3). Median (IQR) 153 (49–255) 188 (96–350) 180.5 (57–238) S-MT vs. TT
Current CD4 (cells/mm3). Median (IQR) 560 (440–754) 669.5 (499.5–962) 617.5 (463.5–815) S-MT vs. TT
Years virologically suppressed. Median (IQR) 4.8 (2.9–8.9) 7.2 (3.3–9.2) 7.8 (5.4–10.7) L-MT vs. TT
Prior blip. N (%) 20 (21.1) 5 (12.5) 9 (16.1) S-MT vs. TT
TT = Triple therapy. S-MT= Short-term Monotherapy. L-MT = Long-term Monotherapy. NA= not applicable.
doi:10.1371/journal.pone.0069493.t001
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Neurocognitive performance
We found no differences in neurocognitive performance
measured by GDS among triple-drug therapy (median GDS:
0.31, IQR: 0.08–0.54), S-MT (0.27, IQR: 0–0.62) and L-MT
groups (0.24, IQR: 0.08–0.54, Figure 1). Rates of impairment in
each of the neurocognitive domains assessed were also similar
across the three groups.
We identified 52 patients (27.2%, 95% CI: 20.9–33.6) with
neurocognitive impairment. All were mild symptomatic (14–
26.9%) or asymptomatic (38–73.1%) by self-report. We did not
observe differences in the prevalence of neurocognitive impair-
ment among triple-drug therapy (31.6%, 95% CI: 22.1–41.0), S-
MT (25.0%, 11.3–38.7) and L-MT (21.4%, 10.5–32.3) groups
(Figure 2).
We also determined the prevalence of neurocognitive impair-
ment based on the presence or absence of medical, psychiatric or
neurologic comorbidities. In the L-MT group the prevalence of
neurocognitive impairment did not change significantly depending
on the presence of comorbidities; in the other two groups, patients
with neurologic comorbidities showed a higher frequency of
neurocognitive impairment (58.3% for the triple therapy group
and 50% for the S-MT - Figure 2).
Logistic regression results
In the univariate analysis, monotherapy (either short-term or
long-term duration) did not show any association to neurocogni-
tive impairment when compared to triple therapy. Total duration
of ART, years of education, ethnicity, transmission route and the
HOMA index modified the association of monotherapy and
neurocognitive impairment more than15%. After adjusting for all
these variables in a multivariate analysis (table 3), no effect on
neurocognitive impairment of S-MT was found (OR 0.85; 95% CI
0.29–2.50; p = 0.76), while L-MT tended to be inversely associated
with the presence of neurocognitive impairment (OR 0.40; IC
95% 0.14–1.15, p = 0.09).
Discussion
We have not found an association between protease inhibitor
monotherapy with darunavir or lopinavir and higher rates of
neurocognitive impairment. Patients maintaining plasma virologic
suppression with protease inhibitor monotherapy did not show an
increased presence of neurocognitive impairment compared to
patients receiving suppressive triple therapy. Moreover, adjusted
odds ratios did not show a trend towards a higher probability of
neurocognitive impairment in patients receiving protease inhibitor
monotherapy for more than two years. The use of established
criteria [14] for diagnosis of neurocognitive impairment including
Table 2. Treatment characteristics and comorbid conditions.
TT N = 95 S-MT (1–2 years) N = 40 L-MT (.2 years) N = 56 p,0.05
Years of antiretroviral therapy. Median (IQR)
Total 10.7 (4.8–15.7) 14.9 (11.0–16.6) 13.4 (10.0–15.0) S-MT, L-MT vs. TT
Triple Therapy 10.7 (4.8–15.7) 13.2 (9.5–15.4) 9.9 (5.2–11.7) S-MT vs. L-MT
Monotherapy NA 1.5 (1.2–1.8) 3.0 (2.6–4.9) S-MT vs. L-MT
Current protease inhibitor. N (%) S-MT vs. TT, L-MT
Darunavir/ritonavir 25 (26.3) 24 (60.0) 19 (33.9)
Lopinavir/ritonavir 70 (73.7) 16 (40.0) 37 (66.1)
Adherence level ,100%. N (%) 25 (27.8) 7 (18.0) 11 (19.6)
CPE score. Median (IQR) 7 (7–7) 3 (3–3) 3 (3–3) NA
Use of non-prescribed drugs. N (%)
Never 43 (46.7) 19 (47.5) 31 (55.4)
Past 25 (27.2) 12 (30.0) 14 (25.0)
Active 24 (26.1) 9 (22.5) 11 (19.6)
Prior neurological disease. N (%) 12 (12.6) 4 (10.0) 6 (10.7)
Prior psychiatric disease. N (%) 19 (20.0) 9 (22.5) 15 (26.8)
HADS-D score. Median (IQR) 2 (0–5) 2 (0.5–3.5) 2.5 (1–5)
Prior medical disease*. N (%) 35 (36.8) 22 (55.0) 27 (48.2)
Hepatitis C. N (%)
No 48 (52.8) 17 (42.5) 35 (63.6)
Past 19 (20.9) 10 (25.0) 14 (25.5)
Active 24 (26.4) 13 (32.5) 4 (10.9) S-MT vs. L-MT
Triglycerides (mg/dL). Median (IQR) 136.5 (108–197) 176.5 (138–209.5) 189 (124–272) L-MT vs. TT
Total Cholesterol/HDL ratio. Median (IQR) 3.9 (3.3–4.7) 4.6 (3.6–5.6) 4.3 (3.3–5.9) S-MT vs. TT
Receiving statins. N (%) 14 (15.9) 9 (22.5) 17 (32.1) L-MT vs. TT
HOMA index. Median (IQR) 1.7 (1.1–2.7) 2.1 (1.3–4.0) 2.2 (1.4–3.4) L-MT vs. TT
TT = Triple therapy. S-MT= Short-term Monotherapy. L-MT = Long-term Monotherapy. Medical disease: hypertension, dyslipidemia, diabetes mellitus, ischemic heart
disease, heart insufficiency, chronic renal failure, thyroid disorders and peripheral arterial disease*.
doi:10.1371/journal.pone.0069493.t002
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demographically corrected norms and the blinding of the
psychologist administering the neuropsychological tests strengthen
our findings.
Despite a potential weakness to suppress HIV replication in the
CNS, due to a low CPE score [8,16], patients on protease inhibitor
monotherapy maintaining plasma virologic suppression did not
show increased rates of neurocognitive impairment. Studies that
have evaluated neurocognitive impairment rates according to CPE
score only in suppressed patients have uniformly found no
statistically significant benefit of a higher CPE score in patients
receiving triple-drug ART [17,18,19]. Compared to these studies,
ours had the advantage of comparing patients with a large
difference 24 points- in CPE score. Results of two smaller studies
in which protease inhibitor monotherapy with lopinavir/ritonavir
was not associated with greater rates of neurocognitive impairment
[10,11] also supports our findings.
Our results suggest that protease inhibitor monotherapy with
lopinavir or darunavir in patients with adequate plasma suppres-
sion may be enough to prevent HAND. Protease inhibitor
monotherapy is an option only for patients with long-term plasma
virological suppression and high CD4 cell counts, which is a low
risk scenario for HAND. Virological suppression in plasma
decreases HIV trafficking towards the central nervous system
and a high CD4 cell count decreases the risk of independent HIV
replication in the brain parenchyma [20]. In the event of residual
local brain HIV replication, lopinavir and darunavir achieve levels
Figure 1. Distribution of neurocognitive performance by global deficit score (GDS).
doi:10.1371/journal.pone.0069493.g001
Figure 2. Global prevalence of neurocognitive impairment in each treatment group and by presence of comorbidities.
doi:10.1371/journal.pone.0069493.g002
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in the cerebrospinal fluid that exceed several times the IC50 of the
virus [21,22].
The other hypothesis that could explain our results is a similar
net balance between neuro-protection and neurotoxicity in
patients treated with triple therapy or protease inhibitor mono-
therapy [23]. In vitro experiments have shown that antiretroviral
drugs at concentrations achieved in the cerebrospinal fluid can
produce neural damage [24]. Two clinical studies have also
suggested a possible neurotoxic effect of ART. In ACTG 5170
[25] neuropsychological scores improved after ART interruption.
In ACTG 736 [26] ART regimens with higher CPE score were
associated with poorer neurocognitive performance. It is possible
than in patients receiving protease inhibitor monotherapy a
possible lower neuro-penetrance could be compensated with lower
neurotoxicity.
Our results do not contradict prior reports of other types of
neurological diseases in patients receiving protease inhibitor
monotherapy [11,27]. While our study is focused on neurocogni-
tive impairment, these reports described patients with neurological
symptoms such as meningitis associated to cerebrospinal fluid viral
escape. Reports are heterogeneous because they have included
patients with and without adequate plasma virological suppression
[28]. Neurological disease and cerebrospinal fluid viral escape has
also been communicated in patients receiving triple drug ART
[29,30]. At present it is unclear if patients exposed to protease
inhibitor monotherapy have a higher risk of cerebrospinal fluid
virological escape and neurological disease. In the MONET
clinical trial after three years of follow-up drug-related neuropsy-
chiatric adverse events were infrequent for darunavir/ritonavir,
either used as monotherapy or triple therapy [31].
Our study has significant limitations. We cannot rule out the
possibility of a beta error since we had only a 38% power to detect
differences in prevalence of neurocognitive impairment similar to
the ones found between triple therapy and L-MT. However, in
light our results, it is highly unlikely that the undetected effect
favours the group on triple therapy. Besides, the upper limit of the
95% CI for the prevalence of neurocognitive impairment for
patients who received protease inhibitor monotherapy for more
than two years 232.3%- is consistent with the prevalence of
neurocognitive impairment in suppressed patients receiving triple
therapy [1].
Another limitation of a cross-sectional study like ours is
prescription bias. Protease inhibitor monotherapy is an option
only for patients who have maintained HIV suppression for at
least 6 months, without previous virological failure while on a
protease inhibitor based regimen and preferably without low CD4
nadirs [32]. It is logical that due to these restrictions patients
receiving protease inhibitor monotherapy had slightly different
characteristics than patients receiving triple therapy.
We believe a systematic bias in favour of using monotherapy in
patients with a lower risk of neurocognitive impairment, is
unlikely. Differences between monotherapy and triple therapy
groups had limited clinical relevance. We recruited predominantly
highly adherent, middle age, Caucasian males who acquired HIV
sexually 15 to 20 years ago, started ART with a CD4 nadir within
150 to 200 cells/mL, who were virologically suppressed for 5 to 8
years and had similar education and past history of medical,
neurological and psychiatric disease.
Finally, since our analysis is cross-sectional, survivor bias might
have confounded results. It is possible that patients who developed
neurocognitive impairment while on protease inhibitor monother-
apy changed ART before entering the present study. Patients
enrolled in our cohorts that switched protease inhibitor mono-
therapy to other regimens prior to the initiation of the study,
changed ART mainly due persistent low-level viremia in plasma
and we did not identify a single case of switching due to
neurocognitive complains. However, we cannot exclude that the
detection of plasma low-level viremia in those patients could be
associated with a reduction in the rates of adherence due to
asymptomatic neurocognitive impairment.
In summary, our study does not confirm an association between
protease inhibitor monotherapy and neurocognitive impairment,
even in patients receiving monotherapy for a prolonged period of
time. These results question the importance of using multiple
drugs with potential activity in the CNS to prevent neurocognitive
impairment.
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Crude 0.72 (0.31–1.67) 0.59 (0.27–1.28)
Step 1 Total duration of ART 0.94 (0.39–2.31) 0.60 (0.26–1.39)
Step 2 Years of education 0.77 (0.29–1.99) 0.43 (0.17–1.07)
Step 3 Ethnicity 0.99 (0.37–2.65) 0.51 (0.20–1.33)
Step 4 Transmission route 1.07 (0.39–2.94) 0.41 (0.15–1.13)
Step 5 HOMA index 0.85 (0.29–2.50) 0.40 (0.14–1.15)
FINAL
MODEL
0.85 (0.29–2.50) 0.40 (0.14–1.15)
S-MT= Short-term Monotherapy. L-MT = Long-term Monotherapy.
doi:10.1371/journal.pone.0069493.t003
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